Australian medical device company Ventracor is so pleased with its clinical trial design, it's decided to apply for a patent for it.

The July/August 2008 issue of Australian Life Scientist is out now.

Apollo aborts mission, investment fund licensed, biotechs move into Phase II trials and NuSep sorts its sperm.

Melbourne company Invision IT says its Evado software overcomes EDC shortcomings.

With AusBiotech 2007 being held in Brisbane next week, ALS takes its bi-annual survey of the state of the industry.

Ventracor's LVAD device is now on the market.

It hasn't been the best year on record for the Australian biotechnology industry but things should improve somewhat next year. Kate McDonald reports that the fragility of the sector is sure to be a topic of discussion at this year's AusBiotech conference.

Artificial heart company Ventracor (ASX: VCR) has implanted its 50th VentrAssist left ventricular assist device (LVAD) and has reached the enrolment target of 30 implants in its European CE Mark trial.

Artificial heart company Ventracor (ASX:VCR) has implanted its fifth VentrAssist left ventricular assist system (LVAS) in the United States.

Paul Trainor AO, 78, 'father of Australia's medical device industry' died on January 13, 2006.

Following a board stoush last year and calls by shareholders at the company's AGM for a change in management, Polartechnics (ASX:PLT) CEO Victor Skladnev was yesterday replaced by Ben Dillon.